Lion Point Capital, L.P. 13F annual report
Lion Point Capital, L.P. is an investment fund managing more than $31.9 billion ran by Irshad Karim. There are currently 23 companies in Mr. Karim’s portfolio. The largest investments include Ardelyx Inc and Insmed Inc, together worth $11.1 billion.
$31.9 billion Assets Under Management (AUM)
As of 7th August 2024, Lion Point Capital, L.P.’s top holding is 856,667 shares of Ardelyx Inc currently worth over $6.35 billion and making up 19.9% of the portfolio value.
Relative to the number of outstanding shares of Ardelyx Inc, Lion Point Capital, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 70,335 shares of Insmed Inc worth $4.71 billion, whose value grew 178.4% in the past six months.
The third-largest holding is Milestone Pharmaceuticals In worth $3.09 billion and the next is Geron worth $2.67 billion, with 630,000 shares owned.
Currently, Lion Point Capital, L.P.'s portfolio is worth at least $31.9 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Lion Point Capital, L.P.
The Lion Point Capital, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Irshad Karim serves as the General Counsel and Chief Compliance Officer at Lion Point Capital, L.P..
Recent trades
In the most recent 13F filing, Lion Point Capital, L.P. revealed that it had opened a new position in
Kiniksa Pharmaceuticals Intl and bought 104,691 shares worth $1.95 billion.
The investment fund also strengthened its position in Milestone Pharmaceuticals In by buying
40,000 additional shares.
This makes their stake in Milestone Pharmaceuticals In total 2,340,207 shares worth $3.09 billion.
On the other hand, there are companies that Lion Point Capital, L.P. is getting rid of from its portfolio.
Lion Point Capital, L.P. closed its position in Kiniksa Pharmaceuticals International Plc on 14th August 2024.
It sold the previously owned 130,691 shares for $2.58 billion.
Irshad Karim also disclosed a decreased stake in Ardelyx Inc by 0.2%.
This leaves the value of the investment at $6.35 billion and 856,667 shares.
One of the smallest hedge funds
The two most similar investment funds to Lion Point Capital, L.P. are Chicago Capital Management and Richmond Brothers. They manage $31.9 billion and $32 billion respectively.
Irshad Karim investment strategy
Lion Point Capital, L.P.’s portfolio is diversified across 6 sectors.
Currently, their heaviest sector is Health Care — making up 74.3% of
the total portfolio value.
The fund focuses on investments in the United States as
82.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
17% of the total holdings value.
On the other hand, large-cap stocks make up 13.0% of the portfolio.
The average market cap of the portfolio companies is close to $156 billion.
The complete list of Lion Point Capital, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ardelyx Inc |
18.15%
856,667
|
$6,347,902,000 | 19.89% |
| Insmed Inc |
No change
70,335
|
$4,712,445,000 | 14.77% |
| Milestone Pharmaceuticals In |
1.74%
2,340,207
|
$3,089,073,000 | 9.68% |
| Geron Corp. |
5.00%
630,000
|
$2,671,200,000 | 8.37% |
| Kiniksa Pharmaceuticals International Plc. |
Closed
130,691
|
$2,578,533,000 | |
| Marinus Pharmaceuticals Inc |
0.20%
2,114,827
|
$2,474,348,000 | 7.75% |
| Kiniksa Pharmaceuticals Intl |
Opened
104,691
|
$1,954,581,000 | 6.12% |
| Avadel Pharmaceuticals plc |
Closed
82,500
|
$1,393,425,000 | |
| Syndax Pharmaceuticals Inc |
No change
65,000
|
$1,334,450,000 | 4.18% |
| BridgeBio Pharma Inc |
Opened
49,000
|
$1,241,170,000 | 3.89% |
| Avadel Pharmaceuticals plc |
Opened
82,500
|
$1,159,950,000 | 3.63% |
| Neurocrine Biosciences, Inc. |
11.33%
8,350
|
$1,149,545,000 | 3.60% |
| Fennec Pharmaceuticals Inc |
No change
170,000
|
$1,038,700,000 | 3.25% |
| Mineralys Therapeutics Inc |
31.67%
79,000
|
$924,300,000 | 2.90% |
| Enphys Acquisition Corp. |
No change
78,125
|
$857,813,000 | 2.69% |
| Humacyte Inc |
Closed
235,000
|
$730,850,000 | |
| Jasper Therapeutics Inc |
No change
32,000
|
$726,400,000 | 2.28% |
| Bluebird bio Inc |
20.04%
678,256
|
$667,540,000 | 2.09% |
| Travere Therapeutics Inc |
Closed
78,000
|
$601,380,000 | |
| BurgerFi International, Inc. |
No change
2,745,938
|
$557,425,000 | 1.75% |
| Regenxbio Inc |
11.54%
36,250
|
$424,125,000 | 1.33% |
| Replimune Group Inc |
Closed
42,500
|
$347,225,000 | |
| Seres Therapeutics Inc |
No change
340,761
|
$246,643,000 | 0.77% |
| Lumos Pharma Inc |
No change
90,794
|
$210,642,000 | 0.66% |
| Microsoft Corporation |
No change
100
|
$44,695,000 | 0.14% |
| Spruce Biosciences, Inc. |
No change
75,000
|
$38,828,000 | 0.12% |
| Battalion Oil Corp |
62.75%
7,423
|
$24,793,000 | 0.08% |
| Alphabet Inc |
No change
100
|
$18,342,000 | 0.06% |
| Semtech Corp. |
Closed
14
|
$385,000 | |
| No transactions found | |||
| Showing first 500 out of 29 holdings | |||
Hedge funds similar to Lion Point Capital, L.P.
- Janney Montgomery Scott
- Acadian Asset Management
- Strategic Income Management
- Qualcomm Inc/de
- Amia Capital LL.P.
- Pariax
- Richmond Brothers
- Chicago Capital Management
- Lewin Nick
- Biglari, Sardar
- Vahanian & Associates Planning
- Certares Management
- Envoi
- Systematic Portfolios